QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Concizumab Mechanism, Clinical Safety and Pharmacovigilance

Test your understanding of the concepts covered by Concizumab: Mechanism, Clinical Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which finding would provide the strongest evidence that a suspected thrombotic event actually occurred?

A report that the patient felt generally unwell. A temporal association with a concizumab dose alone. Diagnostic confirmation identifying the event and anatomical site, together with clinical course and treatment. A normal routine coagulation test.

Question 2 of 10 Which operational control would most directly reduce the risk of losing clinically important exposure information in concizumab cases?

A medical-review prompt requiring documentation of factor or bypassing-agent exposure. A rule that permits recording only the prophylactic antibody. A rule that collapses all medicines into a single product field. A requirement to use PT as the primary pharmacodynamic assessment.

Question 3 of 10 An aggregate review shows an increase in thrombotic reports after a change in reporting practice and increased use of rescue treatment. What is the most appropriate next step?

Declare a confirmed new risk based solely on the report count. Dismiss the pattern because reporting practice changed. Review exposure denominators, reporting effects, treatment patterns and individual case narratives before classifying the signal. Pool all cases across haemophilia populations without stratification.

Question 4 of 10 Which statement most accurately distinguishes a labelled risk from individual-case causality?

A labelled risk proves that the product caused every similar event. A labelled risk is irrelevant to individual case assessment. A labelled risk informs the clinical context but does not eliminate the need for case-specific chronology, alternatives and evidence. A labelled risk means that no follow-up is necessary.

Question 5 of 10 Which conclusion about a patient alert card or educational material is most appropriate?

Distribution alone proves that risk minimisation was effective. Possession of the card establishes that the patient followed all precautions. Distribution can demonstrate a process step, but effectiveness requires evidence related to understanding, recognition or management of risk. The card replaces the need to document concomitant haemostatic treatment.

Question 6 of 10 What is the most appropriate interpretation of a thrombotic event occurring while a patient is exposed to concizumab and a bypassing agent?

The event is automatically caused by concizumab. The event is automatically caused by the bypassing agent. The combined exposure is clinically relevant, but causality requires chronology, objective evidence, alternatives and medical reasoning. The event cannot be drug-related because more than one product was involved.

Question 7 of 10 Which set of factors represents appropriate competing or interacting explanations to review in a suspected thrombotic event?

Only the patient’s concizumab dose and injection site. Prior thrombosis, cardiovascular disease, immobility, surgery, malignancy, sepsis and concurrent haemostatic treatment where relevant. Only whether the patient had a normal PT. Only the presence or absence of an alert card.

Question 8 of 10 Why must a concizumab safety case include details of factor or bypassing-agent treatment given for a breakthrough bleed?

Those treatments may materially alter the haemostatic balance and interpretation of the outcome. They are required only to determine whether the patient received the correct injection technique. They replace the need to document concizumab dose and administration dates. They are relevant only when the event is classified as a product-quality complaint.

Question 9 of 10 Which chronology is most useful when evaluating a suspected thrombotic event in a patient receiving concizumab?

Only the date on which thrombosis was diagnosed. Concizumab prophylaxis, any interruption or restart, breakthrough bleeding, haemostatic treatment, and thrombotic-event onset and confirmation. Only the most recent concizumab injection and the patient’s age. The patient’s coagulation-test results without treatment history.

Question 10 of 10 A company sends a follow-up request but receives no returned information. How should this be represented in the case process?

The case should be marked as medically assessed because a request was sent. The missing information should be treated as obtained unless the reporter explicitly refuses it. The system should distinguish the request from completed follow-up and document the resulting uncertainty. The case should be closed automatically as invalid.

QPPV.com

Professional Knowledge Assessment: Concizumab Mechanism, Clinical Safety and Pharmacovigilance

Cookie Settings